

Monothematic Conference

May 22-23, 2025

Liquid Biopsy in BTC: from bench to bedside

Conference Pedro M. Rodrigues (San Sebastian, Spain)
Directors Tian Tian (Barcelona, Spain)
Local Organizer Miriam Sanso Martínez (Mallorca, Spain)

Day 1		Liquid Biopsy in BTC: from bench to bedside		22/5
TIME (CEST)	TITLE		SPEAKER	
08:00-08:50	Registration, badge & material delivery			
08:50-9:00	>Welcome words	Pedro M. Rodrigues (Spain) / Tian Tian (Spain) / Miriam Sanso Martínez (Spain) Rocío Macías (Spain) / Chiara Braconi (UK)		
9:00-10:30	SESSION 1: GENERAL OVERVIEW OF BTC AND CURRENT DIAGNOSTIC PIPELINE			
	Moderators:	Chiara Braconi (UK) / Bledar Kraja (Albania)		
9:00 - 9:15	Natural course of BTC	Trine Folseraas (Norway)		
9:15 - 9:30	An historical overview of CA19.9: from discovery to clinical application	Bruno Sangro (Spain)		
9:30 - 09:45	Molecular diagnosis of BTC	Tim Kendall (UK)		
9:45 - 10:00	Conquering hurdels of liquid biopsy analyses for the detection of BTC	Guro Lind (Norway)		
		With the addition of:		
		Teresa Macarulla (Spain)		
		Cindy Neuzillet (France)		
		Guido Carpino (Italy)		
		Vincenzo Cardinale (Italy)		
10:00 - 10:15	Round table & Discussion			
10:15 - 10:45	Coffee break and poster session			
10:45-12:30	SESSION 2: FROM BIOMARKER DISCOVERY TO CLINICAL IMPLEMENTATION			
	Moderators:	Pedro M. Rodrigues (Spain) / Tian Tian (Spain)		
10:30 - 10:45	Applications of ctDNA in clinical practice	Anna Saborowski (Germany)		
10:45 - 11:00	Next generation biomarkers for BTC	Jesus M. Banales (Spain)		
11:00 - 11:15	An example of clinical implementation: OWLiver test for MASH diagnosis	Cristina Alonso (Rubio Metabolomics)		
11:15 - 11:30	Patenting and intellectual property	Salvatore Cappadona (Spain)		
11:30 - 11:45	Steps for translating novel discoveries into clinics: a perspective form European Regulatory Bodies	TBA		
		With the addition of:		
		Juan Valle (CCF)		
		Stacie Lindsey (CCF)		
		Helen Morement (AMMF)		
		Stephen Rossi (PSC Partners US)		
		Martine Walmsley (PSC Support UK)		
11:45 - 12:30	<u>Round table</u> : How to translate novel biomarkers into clinics? A step-by-step guide			
12:30 - 13:30	Lunch and poster session			
13:30 - 13:50	Independent Medical Education Session			
	Moderators:	TBA (TBA)		
13:30 - 13:50	HER2-Amplified Advanced Biliary Tract Cancer: Exploring the Utility of Liquid Biopsy for Patient Identification	Florian Castet (Spain)		
13:50 - 14:50	SESSION 3: ABSTRACT-BASED SESSION			
	Moderators:	Rui E. Castro (Portugal) / Constantinos Athanassopoulos (Greece)		
13:50 - 14:05	Longitudinal liquid biopsy in patients with biliary tract cancer undergoing systemic treatment	Giulia Tesini (UK)		
14:05 - 14:20	Extracellular Vesicle Profiling for Treatment Response Prediction in Advanced Biliary Tract Cancer	Michele Zanoni (Italy)		
14:20 - 14:35	Bile extracellular vesicles contain protein biomarkers for early cholangiocarcinoma diagnosis in primary sclerosing cholangitis	Ainhua Lapitz (Spain)		
14:35 - 14:50	Upregulated Glycolysis and SLC2A3 Expression in iCCA: Implications for Tumor Aggressiveness and Progno:	Michela Polidoro (Italy)		
14:50 - 15:30	Keynote Lecture			
	Moderators:	Miriam Sanso Martinez (Spain)		
14:50 - 15:30	Translating liquid biopsies into clinics: lessons learnt from other cancers	Klaus Pantel (Germany)		
15:30-16:00	Coffee break and poster session			

16:00 - 17:30		SESSION 4: BIOMARKERS OF RESPONSE TO THERAPY	
	<i>Moderators:</i>	TBA (TBA) / Dominique Scherer (Germany)	
16:00 - 16:15	Oncological treatment of BTC		Erman Akkus (Turkey)
16:15 - 16:30	Biomarkers of treatment response: are we there yet?		Cindy Neuzillet (France)
16:30 - 16:45	Tracking drug resistance in BTC: the role of liquid biopsy in Precision Oncology		Lipika Goyal (USA)
16:45 - 17:00	New therapies for BTC: what's next?		Arndt Vogel (Canada)
			<i>With the addition of:</i>
17:00 - 17:15	Panel Discussion		Juan Valle (CCF)
			Chiara Braconi (UK)
			Jesus M. Banales (Spain)
17:15 - 19:15	PRECISION-BTC NETWORK MANAGEMENT COMMITTEE (MC) MEETING [<i>Invitation only</i>]		
20:30	JOINT DINNER		

Day 2	Precision-BTC Network Annual Conference		23/5
TIME	TITLE	SPEAKER	
08:00 - 08:50	Registration, badge & material delivery		
08:50 - 9:00	Welcome words	Rocío Macías (Spain) / Chiara Braconi (UK)	
9:00 - 10:00	SESSION 1: WG1 - Identification of epidemiological heterogeneity in Europe		
	Moderators:	Marcin Krawczyk (Poland) / Chiara Gabbi (Sweden)	
09:00 - 09:15	Consensus Statement on Ampullary carcinoma	Ana Landa (Spain)	
09:15 - 09:30	Liquid Biopsy for Gallbladder Cancer: Design and Results of the EULAT Eradicate GBC Consortium	Dominique Scherer (Germany)	
09:30 - 09:45	Cholangiocarcinoma in individuals with chronic liver disease is diagnosed earlier, leading to better prognosis	Laura Izquierdo (Spain)	
09:45 - 10:45	SESSION 2: WG3 - Personalisation of treatment for patients with BTC		
	Moderators:	Anne Demols (Belgium) / Angela Lamarca (Spain)	
09:45 - 10:00	Updates on SAFIR (ABC10) clinical trial	John Bridgewater (UK)	
10:00 - 10:15	Genomic alterations in biliary tract cancer and association with patient outcomes: translational data from the BILCAP clinical trial	Valerie Crowley (UK)	
10:15 - 10:25	Unveiling the secrets of real-world use of Zanidatamab in an English biliary tract cancer cohort	Marina Izaskun Crespo Cruz (UK)	
10:25 - 10:35	Preliminary Exploration of Activated Mast Cells in Cholangiocarcinoma Subtype with Fibrotic Tumor Microen	Nataliya Rohr-Udilova (Austria)	
10:35 - 10:45	Clinically effective biliary drainage and systemic therapy rather than intraductal radiofrequency ablation improve overall	Monica State (Romania)	
10:45-11:15	Coffee break and poster session		
11:15 - 12:00	SESSION 3: WG4 - Patient-centric support management		
	Moderators:	Antonella Cammarota (Italy) / Mohamed Bouattour (France)	
11:15 - 11:30	QoL in BTC: aggregated trial data	Luka Cavka (Slovenia)	
11:30 - 11:35	Patient advocacy in Cholangiocarcinoma - an AMMF perspective	Helen Morement (UK)	
11:35 - 11:40	Patient advocacy in Cholangiocarcinoma - an ATUVIBI perspective	Elisabeth Baucells (Spain)	
11:40 - 11:45	Patient advocacy in Cholangiocarcinoma - an APIC perspective	Paolo Leonardi (Italy)	
11:45 - 12:00	Identifying Gaps in Provider Practices and Patient Education of Cholangiocarcinoma Screening and Surveillance: Results of a Multinational PSC Patient Survey	Stephen Rossi (USA)	
12:00-13:00	Lunch and poster session		
13:00 - 14:00	SESSION 4: WG5 - Artificial Intelligence		
	Moderators:	Jesper Andersen (Denmark) / Qinghe Zeng (Germany)	
13:00 - 13:15	AI-DELPHI: A consensus statement from the Precision-BTC Network	Colm O'Rourke (Denmark)	
13:15 - 13:30	Combination of Artificial Intelligence and Spatial Transcriptomics to Decode Liver Cancer Heterogeneity	Qinghe Zeng (Germany)	
13:30 - 13:40	Artificial Intelligence-Assisted Electrochemical Biosensor for Urine-Based Detection of Biliary Tract Cancer via Liquid Biopsy	Onur Karaman (Turkey)	
13:40 - 13:50	Prognostic tissue biomarkers for cholangiocarcinoma after tumor resection: from systematic review and meta-analysis to multicenter international validation	Beatriz Val (Spain)	
13:50 - 14:00	Application of machine learning and molecular docking to the modelling and design of HDAC6/ROCK dual inhibitors with <i>in vitro</i> experimental validation	Milan Beljkas (Serbia)	

14:00 - 15:30 SESSION 5: WG6 - Drug development using preclinical models		
Moderators: Laura Fouassier (France) / Marta B. Afonso (Portugal)		
14:00 - 14:15	NOX4/NOX1 dual inhibition in cholangiocarcinoma as an effective approach to target TGF-beta protumorigenic actions in cancer-associated fibroblasts	Javier Vaquero (Spain)
14:15 - 14:30	Defining the pre-cursor cell states that give rise to cholangiocarcinoma	Luke Boulter (UK)
14:30 - 14:45	Mapping the tumor microenvironment in intrahepatic cholangiocarcinoma	Monique Verstegen (Netherlands)
14:45 - 14:55	Deciphering the role of PDL1 in shaping the Tumor Microenvironment in Cholangiocarcinoma using a CCA-on-chip platform	Sofia Buzzi (Italy)
14:55 - 15:05	Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma	Mirko Minini (France)
15:05 - 15:15	Investigating the role of a natural compound as a Hedgehog inhibitor in the management of Intrahepatic Cholangiocarcinoma	Savino Paradiso (Italy)
15:15 - 15:25	Could the AptLipo-SoroMitoPAC drug delivery system targeted with aptamer CA19-9 be a new drug candidate for intrahepatic cholangiocarcinoma?	Ozge Cevik (Turkey)
15:25 - 15:30	Closing remarks and farewell	Rocío Macías (Spain) / Chiara Braconi (UK)

Supported by:



With the participation and scientific support of:

